Regulus Therapeutics Inc

Regulus Therapeutics — Rare & Orphan Disease Summit (May 2021)

30 slides from Regulus Therapeutics's conference presentation, May 21, 2021

  1. Slide 1: Corporate Presentation – Rare & Orphan Disease Summit

    Corporate Presentation Rare & Orphan Disease Summit May 21st, 2021 Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to underta

  3. Slide 3: Regulus Recent Highlights

    Advancing RGLS4326 in Phase 1b study of patients with ADPKD Demonstrated target engagement with significant increase in key biomarkers in first cohort of patients Safety profile encouraging with anticipated pharmacokinetic properties as well Completing preparations for planned FDA engagement mid-yea

  4. Slide 4: Regulus Therapeutics Overview

    Regulus Therapeutics Overview Leading microRNA company focused on translating novel technology into first in class, innovative therapeutics Pioneering microRNA therapeutics targeting genetic kidney disease in the clinic with RGLS4326 in ADPKD and Lademirsen (RG-012) in Alport Syndrome Advancing focu

  5. Slide 5: Research & Development Pipeline

    Research & Development Pipeline Target Validation Lead Optimization IND enabling Phase 1 Phase 2 Phase 3 Nephrology Alport Syndrome lademirsen* ADPKD** RGLS4326 ADPKD NextGen Research Programs Other Research Programs*** *Formerly RG-012 **Autosomal Dominant Polycystic Kidney Disease *** Examples: In

  6. Slide 6: Sanofi Partnership: Lademirsen for the Treatment of Alport Syndrome

    Clinical demonstration of desired kidney exposure and binding of the target, miR-21 Chronic treatment with lademirsen is well tolerated (Q2W for one year) with no SAEs reported Promising trend in key disease markers Achieved $10m milestone in 2020. Regulus eligible to receive additional $25M develop

  7. Slide 7: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Autosomal Dominant Polycystic Kidney Disease (ADPKD) Orphan disease due to mutations in either PKD1 or PKD2 genes, causing proliferation and fluid-filled cysts in kidneys 85% 160,000 patients with PKD1 mutation diagnosed individuals in U.S. Patient population 50% patients develop ESRD by age 60 Heal

  8. Slide 8: ADPKD: Genetic Renal Disease with High Unmet Need

    ADPKD: Genetic Renal Disease with High Unmet Need Ref: https://pkdcure.org Kidney Function Decline by Age 4th leading cause of kidney failure 50% patients develop kidney failure by age 50 Renal Manifestations Bilateral renal enlargement (up to 35 lb each) multiple fluid-filled cysts, significant ren

  9. Slide 9: Burgeoning Market with Few Competitors

    Burgeoning Market with Few Competitors Jynarque® (tolvaptan, vasopressin V2 antagonist) – only approved therapy in U.S. FDA approval in April 2018 Boxed warning due to potentially fatal liver injury & failure requiring transplant REMS program with restricted distribution and ongoing liver monitoring

  10. Slide 10: RGLS4326 Preliminary Target Product Profile

    RGLS4326 Preliminary Target Product Profile First-in-class anti-miR-17 oligonucleotide with potential as disease-modifying treatment Mechanism of Action Antagonist of miR-17, an overexpressed microRNA that regulates PKD1 and PKD2 expression Efficacy Disease modifying agent to slow progression of cys

  11. Slide 11: RGLS4326 Mechanism of Action

    RGLS4326 Mechanism of Action Direct mechanistic link to ADPKD pathogenesis miR-17 PC1 PC2 PKD1/PKD1 PKD2/PKD2 Direct mRNA Targets Regulated Gene Networks Examples: Normal Kidney Normal Functional Level miR-17 PC1 PC2 PKD1/PKD1mut PKD2/PKD2 Direct mRNA Targets Dysregulated Gene Networks Examples: ADP

  12. Slide 12: miR-17 is Upregulated in Mouse Kidney Cysts and Human ADPKD Cyst Cells

    miR-17 is Upregulated in Mouse Kidney Cysts and Human ADPKD Cyst Cells Human Kidney Samples In-situ hybridization Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 Normal Human Kidney ADPKD Kidney miR-17 probe miR-17 probe Control probe Control probe Mouse Kidney Samples qPCR analysis Normal Kidney

  13. Slide 13: miR-17 Directly Binds PKD1 and PKD2 Genes

    miR-17 Directly Binds PKD1 and PKD2 Genes – the Mutated Genes in ADPKD 3’UTRs of PKD1 and PKD2 contain conserved miR-17 binding sequences miR-17 mimic represses Pkd1 and Pkd2 in mouse collecting duct (IMCD3) cells PNAS 2013 June;110(26): 10765-10770 WT: wildtype 3’UTR MT: mutated 3’UTR PKD1: 3’UTR c

  14. Slide 14: Targeting miR17 Shows Derepression of Pkd1 and Pkd2 in Pkd2-KO Mice

    Age: D1 D10 D11 D12 D19 D28 (18d treatment) Targeting miR17 Shows Derepression of Pkd1 and Pkd2 Gene Expression in Pkd2-KO Mice Inject Lee et al., (2019)10:4148 Nat. Comm.

  15. Slide 15: Targeting miR17 with RGLS4326 Increases Polycystin Levels in Human ADPKD Cyst Cells

    Targeting miR17 with RGLS4326 Increases Polycystin Levels in Human ADPKD Cyst Cells in vitro **p<0.01 *p<0.05 All versus Mock PC1 Expression PC2 Expression * ** Lee et al., (2019)10:4148 Nat. Comm.

  16. Slide 16: Optimized Biomarker Assay Detects PC1 and PC2 in ADPKD Patients

    Optimized Biomarker Assay Demonstrates Ability to Detect PC1 and PC2 in ADPKD Patients and Healthy Volunteers Confirms Correlation with Disease Severity Lower levels of PC1 and PC2 are associated with disease severity based on increased kidney size Preliminary analysis support sample size (n=9) suff

  17. Slide 17: Kidney-specific Knockdown of miR-17~92 Attenuates Disease in ADPKD Mouse Model

    Kidney-specific Knockdown of miR-17~92 Cluster Attenuates Disease in ADPKD Mouse Model (Pkd1F/RC) Hajarnis et al. (2017) Nat Commun. Feb 16;8:14395 MRI Imaging c: Serum Creatinine d: % Proliferation based on number of pHH3+ proliferating cyst epithelial cells

  18. Slide 18: RGLS4326 Preferentially Distributes to the Kidney and Localizes to Renal Cysts

    RGLS4326 Preferentially Distributes to the Kidney and Localizes to Renal Cysts Tissue distribution profile of RGLS4326 based on quantitative whole-body autoradiography in male CD1 mice after a single SC dose of 30mg/kg Representative immunofluorescence image of kidney samples of Pkd2-KO mice after f

  19. Slide 19: RGLS4326 Shows Favorable PK/PD Profiles After a Single SC Dose

    RGLS4326 Shows Favorable PK/PD Profiles After a Single Subcutaneous (SC) Dose of 30 mg/kg Lee et al. (2018) ASN-Kidney Week; Poster Presentation RGLS4326 rapidly absorbed into and cleared from plasma. RGLS4326 distributes primarily to kidney, with kidney-to-liver ratio of >10-fold RGLS4326 potently

  20. Slide 20: RGLS4326 is Efficacious in the Pcy/DBA Mouse Model

    15w (sacrifice) RGLS4326 is Efficacious in the Pcy/DBA Mouse Model Lee et al. (2018) ASN-Kidney Week; Poster Presentation Age: 6w 14w Pcy/DBA: Tolvaptan (Chow; ad libitum) RGLS4326 (QW) Randomized statistically-powered study performed at Regulus; Results confirmed by a blinded study with same study

  21. Slide 21: RGLS4326 Reduces Rate of Kidney Size Expansion in the Pcy/DBA Mouse Model

    RGLS4326 Reduces Rate of Kidney Size Expansion in the Pcy/DBA Mouse Model Changes in body-weight adjusted total kidney volume (bwTKV) from baseline at week 8, 11 and 14 was significantly reduced after RGLS4326 treatment by 25%, 37% and 50%, respectively (p<0.05 for all). Stabilization Reduction Redu

  22. Slide 22: RGLS4326 Clinical Status – Phase 1b MOA Study Underway

    PD biomarkers have been developed to measure changes in both PC1 & PC2 in urinary exosomes Utilizing 13 clinical sites in the US with 12 sites currently actively recruiting Cohort 1- 1 mg/kg SC, Q2W for 4 doses (n≤9) Completed Cohort 2- 0.3 mg/kg SC, Q2W for 4 doses (n≤9) Ongoing Cohort 3- 0.1 mg/kg

  23. Slide 23: RGLS4326 Demonstrated Target Engagement via Increase in Urinary Biomarkers PC1 and PC2

    RGLS4326 Demonstrated Target Engagement in the Kidneys via Increase in Urinary Biomarkers PC1 and PC2 4 x Q2W 1mg/kg subcutaneous injections of RGLS4326 Achieves sufficient exposure in kidneys Inhibits miR-17 function De-represses PKD1 and PKD2 gene expression Increases PC1 and PC2 protein Increases

  24. Slide 24: Data from First Patient Cohort Demonstrate Significant Increase in Biomarkers

    Data from First Patient Cohort Demonstrate Significant Increase in Biomarkers at End of Study Biomarker P1 PC1 0.0004*** PC2 0.0262* 1Based on paired t test comparing day 71 data to baseline

  25. Slide 25: Phase 1b MOA Study: Cohort 1 Top Line Data

    Safety RGLS4326 at 1mg/kg was well tolerated by all nine patients with no serious adverse events reported All reported adverse events were mild and generally transient in nature Pharmacokinetics Overall, the PK profile of RGLS4326 in patients with ADPKD was similar to the PK profile observed in the

  26. Slide 26: Estimated Human Kidney Exposures

    Estimated Human Kidney Exposures Predicted Kidney Exposure in Phase 1b Study After First and Last Doses PK/PD Analysis in C57BL Mice At 7 Days Past Single Dose PK/PD analysis in mice demonstrated that EC90 is associated with kidney concentration of ~11 μg/g The model predicts that kidney exposures i

  27. Slide 27: Next Generation Anti-miR-17 for ADPKD

    Goal to optimize new compound with improved product profile SAR campaign undertaken to engineer out putative off-target activity believed to underly dose-limiting toxicity seen in chronic toxicity studies in mice and monkeys Maintain beneficial RGLS4326 attributes Preferential kidney exposure and PK

  28. Slide 28: ADPKD Program Summary

    ADPKD Program Summary FDA Lifted Partial Clinical Hold in December 2019 enabling company to resume MAD study Completion of chronic toxicity studies and satisfactory safety margins enabled re-initiation of Phase 1 studies in healthy volunteers and patients with ADPKD Healthy volunteer portion (SAD/MA

  29. Slide 29: Potential Upcoming Catalysts

    Potential Upcoming Catalysts Catalyst Potential Timing FDA engagement for feedback on approach to addressing remaining hold requirements Mid 2021 Topline data for remaining RGLS4326 Phase 1b cohorts Cohort 2 data (0.3 mg/kg) Initiation of Cohort 3 (dose TBD) Q3 2021 Q4 2021 Potential resolution of r

  30. Slide 30: Rare & Orphan Disease Summit May 21st, 2021

    Corporate Presentation Rare & Orphan Disease Summit May 21st, 2021

Regulus Therapeutics — Rare & Orphan Disease Summit (May 2021) on 6ix